Technical Analysis for VYGR - Voyager Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 8.5 -0.47% -0.04
VYGR closed down 0.47 percent on Thursday, January 17, 2019, on 70 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical VYGR trend table...

Date Alert Name Type % Chg
Jan 17 New 52 Week Closing Low Bearish 0.00%
Jan 17 Bollinger Band Squeeze Range Contraction 0.00%
Jan 17 Stochastic Reached Oversold Weakness 0.00%
Jan 17 Down 3 Days in a Row Weakness 0.00%
Jan 17 Down 4 Days in a Row Weakness 0.00%
Jan 17 Down 5 Days in a Row Weakness 0.00%
Jan 17 Oversold Stochastic Weakness 0.00%
Jan 16 New 52 Week Closing Low Bearish -0.47%
Jan 16 Bollinger Band Squeeze Range Contraction -0.47%
Jan 16 BB Squeeze + Lower Band Touch Range Contraction -0.47%

Older signals for VYGR ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system (CNS). The company focuses in the field of adeno-associated virus gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease; and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich's ataxia, and VY-HTT01 for Huntington's disease, as well as VY-SMN101 for neuromuscular disease. The company has strategic collaborations with Genzyme Corporation and the University of Massachusetts Medical School. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Is VYGR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 31.91
52 Week Low 8.3
Average Volume 333,448
200-Day Moving Average 16.776
50-Day Moving Average 10.6027
20-Day Moving Average 9.111
10-Day Moving Average 9.089
Average True Range 0.591
ADX 35.64
+DI 10.2684
-DI 22.7583
Chandelier Exit (Long, 3 ATRs ) 8.377
Chandelier Exit (Short, 3 ATRs ) 10.073000000000001
Upper Bollinger Band 9.7843
Lower Bollinger Band 8.4377
Percent B (%b) 0.05
BandWidth 14.779936
MACD Line -0.5559
MACD Signal Line -0.5967
MACD Histogram 0.0408
Fundamentals Value
Market Cap 228.68 Million
Num Shares 26.9 Million
EPS -2.31
Price-to-Earnings (P/E) Ratio -3.68
Price-to-Sales 69.72
Price-to-Book 5.32
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.06
Resistance 3 (R3) 9.10 8.96 8.96
Resistance 2 (R2) 8.96 8.82 8.94 8.93
Resistance 1 (R1) 8.73 8.73 8.66 8.69 8.90
Pivot Point 8.59 8.59 8.56 8.57 8.59
Support 1 (S1) 8.36 8.45 8.29 8.32 8.10
Support 2 (S2) 8.22 8.36 8.20 8.07
Support 3 (S3) 7.99 8.22 8.04
Support 4 (S4) 7.95